Skip to Content

Dotarem Approval History

  • FDA approved: Yes (First approved March 20th, 2013)
  • Brand name: Dotarem
  • Generic name: gadoterate meglumine
  • Dosage form: Injection
  • Company: Guerbet
  • Treatment for: Diagnosis and Investigation

Dotarem (gadoterate meglumine) is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI).

Development History and FDA Approval Process for Dotarem

Sep  5, 2017Approval FDA Approves Guerbet's Dotarem (gadoterate meglumine) for Pediatric Patients Younger Than Two Years
Mar 20, 2013Approval FDA Approves Dotarem, a New Magnetic Resonance Imaging Agent
Feb 15, 2013Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem (gadoterate meglumine)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.